Welcome to our dedicated page for Halozyme Therapeutics news (Ticker: $HALO), a resource for investors and traders seeking the latest updates and insights on Halozyme Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Halozyme Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Halozyme Therapeutics's position in the market.
Halozyme reported strong financial performance for the first quarter of 2024 with revenue increasing 21% YoY to $196 million, net income of $77 million, and adjusted EBITDA of $116 million. The company also announced a $750 million share repurchase program and reiterated its 2024 financial guidance, expecting total revenue of $915 - $985 million, representing YOY growth of 10% - 19%, adjusted EBITDA of $535 - $585 million, and non-GAAP diluted EPS of $3.55 - $3.90, showing YOY growth of 28% - 41%. Halozyme's CEO highlighted ongoing partnerships with argenx and Roche, as well as advancements in its ENHANZE technology.